Day: April 9, 2024

Mainz Biomed Reports Full Year 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023. “This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking ColoFuture and eAArly DETECT studies which demonstrated extraordinary statistical significance for colorectal cancer (CRC) detection and advanced adenomas, a type of pre-cancerous polyp which are considered precursors to colorectal cancer,” commented Guido Baechler, Chief Executive...

Continue reading

Lassila & Tikanoja plc will publish Interim Report January-March on 26 April 2024

Written by Customer Service on . Posted in Public Companies.

Lassila & Tikanoja plc Investor News 9 April 2024 at 3.00 pm Lassila & Tikanoja plc will publish Interim Report January-March on 26 April 2024 Lassila & Tikanoja plc will publish Interim Report January-March on Friday 26 April 2024 at 8.00 am. After publication, the release will be available on the company’s website at www.lt.fi/en. Lassila & Tikanoja will host a webcast for analysts, investors and media on 26 April 2024 at 10.30 am EET. The briefing will be hosted by CEO Eero Hautaniemi and CFO Valtteri Palin. The presentation material will be published on the company’s website. Conference call: You can access the teleconference by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. https://palvelu.flik.fi/teleconference/?id=50049974 Webcast: To...

Continue reading

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Written by Customer Service on . Posted in Public Companies.

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “These early clinical data from this multi-center Phase 1 study in patients with metastatic pancreatic cancer are encouraging and further corroborate our approach for utilizing QN-302 as a potential treatment for advanced pancreatic cancer,” commented Michael Poirier, Qualigen’s Chairman and Chief Executive Officer. “The three pancreatic cancer patients in the trial to date had ultimately failed extensive prior therapy including...

Continue reading

UMeWorld to Debut the World’s First & Only Weight Loss Cooking Oil in the US

Written by Customer Service on . Posted in Public Companies.

MIAMI, April 09, 2024 (GLOBE NEWSWIRE) — UMeWorld Limited (OTC: UMEWF) is excited to announce that the company has secured an exclusive license to use proprietary enzymatic technologies to manufacture and sell DAG weight loss cooking oil across North America, and in particular the United States. In order to capitalize on the exclusive license, UMeWorld plans on constructing a state-of-the-art DAG cooking oil pilot plant in Miami Florida which is slated to break ground in 2024. This ambitious project will usher in a new era for the company as the facility will have the capacity to produce 10,000 tons of DAG cooking oil per year which is estimated to yield a staggering annual revenue of $200 million dollars when operating at 100% capacity. This revolutionary cooking oil not only promises to redefine culinary standards but also promotes...

Continue reading

Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

Written by Customer Service on . Posted in Public Companies.

Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a new agreement with Anthem Blue Cross in California for reimbursement coverage of the Company’s OvaSuiteSM portfolio of risk assessment tests effective June 1, 2024. Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California. “We are very pleased to add Anthem Blue Cross to our list of payers providing coverage for our OvaSuite...

Continue reading

Westwood Launches First Exchange-Traded Fund: Westwood Salient Enhanced Midstream Income ETF (MDST)

Written by Customer Service on . Posted in Public Companies.

A Solution Focused on Generating High Monthly Distributable Income DALLAS, April 09, 2024 (GLOBE NEWSWIRE) — Westwood Holdings Group (WHG), a publicly-traded investment management boutique and wealth management firm, today launched the Westwood Salient Enhanced Midstream Income ETF (NYSE: MDST). The fund is the first Westwood Exchange-Traded Fund (ETF). MDST seeks to deliver current income and capital appreciation by investing in midstream energy companies, defined as companies and master limited partnerships (MLPs) that gather, transport, store and distribute crude oil, natural gas and other energy products. The ETF combines a high conviction, actively managed, energy-focused equity portfolio with an options overlay designed to produce enhanced income distributions for investors. “Energy is an attractive sector that also serves...

Continue reading

Winshear Appoints Patricio Varas as President in Advance of Drill Programme at the Gaban Gold Project in Peru

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) — Winshear Gold Corp. (TSXV: WINS) (‘Winshear’ or the ‘Company’) is pleased to announce the appointment of Mr. Patricio Varas as President of the Company, effective immediately. Mr. Varas is a Professional Geoscientist and Mining Executive with over 38 years’ experience in mineral exploration, mine development and corporate management. He has extensive experience in developing precious and base metal exploration and mining projects around the world. He has played integral roles in the discovery of world class mineral deposits and mines (Santo Domingo Sur Cu-Fe in Chile, Diavik Diamonds – NWT, and Milestone Potash – Saskatchewan), delivery of major feasibility studies and has overseen significant mineral asset sales and corporate transactions. The Company also...

Continue reading

Rockridge Receives Exploration and Drilling Permit for its Flagship Knife Lake Copper Project in Saskatchewan

Written by Customer Service on . Posted in Public Companies.

Vancouver, BC, April 09, 2024 (GLOBE NEWSWIRE) — Rockridge Resources Ltd. (TSX-V: ROCK) (OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge” or the “Company”) is pleased to announce that it has received an Exploration Permit for its 100% owned Knife Lake Copper Project located in Saskatchewan, Canada (the “Knife Lake Project” or “Property”). The permit provides for exploration activities to be conducted over a 3-year period. The Knife Lake Project, consisting of 82 claims totaling 56,865 hectares (140,516 acres), is an advanced-stage copper, silver, zinc and cobalt exploration property in Saskatchewan host to the Knife Lake Deposit. Knife Lake VMS Project Location Map: https://www.rockridgeresourcesltd.com/_resources/images/Knife-Lake-Region-20210331-003.jpg Specifically, the permit covers mineral exploration activities including prospecting,...

Continue reading

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Written by Customer Service on . Posted in Public Companies.

Enrollment to continue to the end of April to accommodate strong patient and site interest NAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial (“CVOT”) evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease (“ASCVD”), whose LDL-C is not adequately controlled, despite being on maximally...

Continue reading

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Written by Customer Service on . Posted in Public Companies.

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation Expands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman’s breast health journey is addressed, starting from the first...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.